Molecular and Epigenetic Profiles of BRCA1-like Hormone-receptor-positive Breast Tumors Identified with Development and Application of a Copy-number-based Classifier

Overview

Journal Breast Cancer Res

Specialty Oncology

Date 2019 Jan 27

PMID 30683142

Citations 4

Authors

Youdinghuan Chen

Yue Wang

Lucas A Salas

Todd W Miller

Kenneth Mark

Jonathan D Marotti

Arminja N Kettenbach

Chao Cheng

Brock C Christensen

Affiliations

Soon will be listed here.

Abstract

Background: BRCA1-mutated cancers exhibit deficient homologous recombination (HR) DNA repair, resulting in extensive copy number alterations and genome instability. HR deficiency can also arise in tumors without a BRCA1 mutation. Compared with other breast tumors, HR-deficient, BRCA1-like tumors exhibit worse prognosis but selective chemotherapeutic sensitivity. Presently, patients with triple negative breast cancer (TNBC) who do not respond to hormone endocrine-targeting therapy are given cytotoxic chemotherapy. However, more recent evidence showed a similar genomic profile between BRCA1-deficient TNBCs and hormone-receptor-positive tumors. Characterization of the somatic alterations of BRCA1-like hormone-receptor-positive breast tumors as a group, which is currently lacking, can potentially help develop biomarkers for identifying additional patients who might respond to chemotherapy.

Methods: We retrained and validated a copy-number-based support vector machine (SVM) classifier to identify HR-deficient, BRCA1-like breast tumors. We applied this classifier to The Cancer Genome Atlas (TCGA) and Molecular Taxonomy of Breast Cancer International Consortium (METABRIC) breast tumors. We assessed mutational profiles and proliferative capacity by covariate-adjusted linear models and identified differentially methylated regions using DMRcate in BRCA1-like hormone-receptor-positive tumors.

Results: Of the breast tumors in TCGA and METABRIC, 22% (651/2925) were BRCA1-like. Stratifying on hormone-receptor status, 13% (302/2405) receptor-positive and 69% (288/417) triple-negative tumors were BRCA1-like. Among the hormone-receptor-positive subgroup, BRCA1-like tumors showed significantly increased mutational burden and proliferative capacity (both P < 0.05). Genome-scale DNA methylation analysis of BRCA1-like tumors identified 202 differentially methylated gene regions, including hypermethylated BRCA1. Individually significant CpGs were enriched for enhancer regions (P < 0.05). The hypermethylated gene sets were enriched for DNA and chromatin conformation (all Bonferroni P < 0.05).

Conclusions: To provide insights into alternative classification and potential therapeutic targeting strategies of BRCA1-like hormone-receptor-positive tumors we developed and applied a novel copy number classifier to identify BRCA1-like hormone-receptor-positive tumors and their characteristic somatic alteration profiles.

Citing Articles

Complex rearrangements fuel ER and HER2 breast tumours.

Houlahan K, Mangiante L, Sotomayor-Vivas C, Adimoelja A, Park S, Khan A Nature. 2025; 638(8050):510-518.

PMID: 39779850 PMC: 11821522. DOI: 10.1038/s41586-024-08377-x.

Extensive epigenomic dysregulation is a hallmark of homologous recombination deficiency in triple-negative breast cancer.

Chen Y, Salas L, Marotti J, Jenkins N, Cheng C, Miller T Int J Cancer. 2024; 156(6):1191-1202.

PMID: 39635770 PMC: 11738659. DOI: 10.1002/ijc.35274.

Homologous Recombination Deficiency Detection Algorithms: A Systematic Review.

Mark L, Terp S, Krarup H, Thomassen M, Pedersen I, Bogsted M Cancers (Basel). 2023; 15(23).

PMID: 38067337 PMC: 10705160. DOI: 10.3390/cancers15235633.

In Silico Identification of a BRCA1:miR-29:DNMT3 Axis Involved in the Control of Hormone Receptors in BRCA1-Associated Breast Cancers.

Santarosa M, Baldazzi D, Armellin M, Maestro R Int J Mol Sci. 2023; 24(12).

PMID: 37373065 PMC: 10298721. DOI: 10.3390/ijms24129916.

Genome-wide methylation analyses identifies Non-coding RNA genes dysregulated in breast tumours that metastasise to the brain.

Pangeni R, Olivaries I, Huen D, Buzatto V, Dawson T, Ashton K Sci Rep. 2022; 12(1):1102.

PMID: 35058523 PMC: 8776809. DOI: 10.1038/s41598-022-05050-z.

References

Roig B, Rodriguez-Balada M, Samino S, Lam E, Guaita-Esteruelas S, Gomes A . Metabolomics reveals novel blood plasma biomarkers associated to the BRCA1-mutated phenotype of human breast cancer. Sci Rep. 2017; 7(1):17831. PMC: 5736621. DOI: 10.1038/s41598-017-17897-8. View

Jones P, Liang G . Rethinking how DNA methylation patterns are maintained. Nat Rev Genet. 2009; 10(11):805-11. PMC: 2848124. DOI: 10.1038/nrg2651. View

Marquard A, Eklund A, Joshi T, Krzystanek M, Favero F, Wang Z . Pan-cancer analysis of genomic scar signatures associated with homologous recombination deficiency suggests novel indications for existing cancer drugs. Biomark Res. 2015; 3:9. PMC: 4443545. DOI: 10.1186/s40364-015-0033-4. View

Lips E, Laddach N, Savola S, Vollebergh M, Oonk A, Imholz A . Quantitative copy number analysis by Multiplex Ligation-dependent Probe Amplification (MLPA) of BRCA1-associated breast cancer regions identifies BRCAness. Breast Cancer Res. 2011; 13(5):R107. PMC: 3262220. DOI: 10.1186/bcr3049. View

Farmer H, McCabe N, Lord C, Tutt A, Johnson D, Richardson T . Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature. 2005; 434(7035):917-21. DOI: 10.1038/nature03445. View

Chen Y, Marotti J, Jenson E, Onega T, Johnson K, Christensen B . Concordance of DNA methylation profiles between breast core biopsy and surgical excision specimens containing ductal carcinoma in situ (DCIS). Exp Mol Pathol. 2017; 103(1):78-83. PMC: 5572810. DOI: 10.1016/j.yexmp.2017.07.001. View

Lips E, Debipersad R, Scheerman C, Mulder L, Sonke G, van der Kolk L . -Mutated Estrogen Receptor-Positive Breast Cancer Shows BRCAness, Suggesting Sensitivity to Drugs Targeting Homologous Recombination Deficiency. Clin Cancer Res. 2016; 23(5):1236-1241. DOI: 10.1158/1078-0432.CCR-16-0198. View

Lips E, Mulder L, Oonk A, van der Kolk L, Hogervorst F, Imholz A . Triple-negative breast cancer: BRCAness and concordance of clinical features with BRCA1-mutation carriers. Br J Cancer. 2013; 108(10):2172-7. PMC: 3670471. DOI: 10.1038/bjc.2013.144. View

Robin X, Turck N, Hainard A, Tiberti N, Lisacek F, Sanchez J . pROC: an open-source package for R and S+ to analyze and compare ROC curves. BMC Bioinformatics. 2011; 12:77. PMC: 3068975. DOI: 10.1186/1471-2105-12-77. View

10.

Watanabe Y, Maeda I, Oikawa R, Wu W, Tsuchiya K, Miyoshi Y . Aberrant DNA methylation status of DNA repair genes in breast cancer treated with neoadjuvant chemotherapy. Genes Cells. 2014; 18(12):1120-30. DOI: 10.1111/gtc.12100. View

11.

Joosse S, Brandwijk K, Devilee P, Wesseling J, Hogervorst F, Verhoef S . Prediction of BRCA2-association in hereditary breast carcinomas using array-CGH. Breast Cancer Res Treat. 2010; 132(2):379-89. DOI: 10.1007/s10549-010-1016-7. View

12.

Lips E, Mulder L, Hannemann J, Laddach N, Vrancken Peeters M, van de Vijver M . Indicators of homologous recombination deficiency in breast cancer and association with response to neoadjuvant chemotherapy. Ann Oncol. 2010; 22(4):870-876. DOI: 10.1093/annonc/mdq468. View

13.

Vollebergh M, Lips E, Nederlof P, Wessels L, Schmidt M, van Beers E . An aCGH classifier derived from BRCA1-mutated breast cancer and benefit of high-dose platinum-based chemotherapy in HER2-negative breast cancer patients. Ann Oncol. 2010; 22(7):1561-1570. PMC: 3121967. DOI: 10.1093/annonc/mdq624. View

14.

Barretina J, Caponigro G, Stransky N, Venkatesan K, Margolin A, Kim S . The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature. 2012; 483(7391):603-7. PMC: 3320027. DOI: 10.1038/nature11003. View

15.

Vollebergh M, Lips E, Nederlof P, Wessels L, Wesseling J, Vd Vijver M . Genomic patterns resembling BRCA1- and BRCA2-mutated breast cancers predict benefit of intensified carboplatin-based chemotherapy. Breast Cancer Res. 2014; 16(3):R47. PMC: 4076636. DOI: 10.1186/bcr3655. View

16.

Johnson K, Koestler D, Fleischer T, Chen P, Jenson E, Marotti J . DNA methylation in ductal carcinoma in situ related with future development of invasive breast cancer. Clin Epigenetics. 2015; 7:75. PMC: 4514996. DOI: 10.1186/s13148-015-0094-0. View

17.

Schouten P, Grigoriadis A, Kuilman T, Mirza H, Watkins J, Cooke S . Robust BRCA1-like classification of copy number profiles of samples repeated across different datasets and platforms. Mol Oncol. 2015; 9(7):1274-86. PMC: 5528812. DOI: 10.1016/j.molonc.2015.03.002. View

18.

Sharma P, Stecklein S, Kimler B, Sethi G, Petroff B, Phillips T . The prognostic value of promoter methylation in early stage triple negative breast cancer. J Cancer Ther Res. 2014; 3(2):1-11. PMC: 4147783. DOI: 10.7243/2049-7962-3-2. View

19.

DAndrea A . BRCA1: a missing link in the Fanconi anemia/BRCA pathway. Cancer Discov. 2013; 3(4):376-8. PMC: 3693462. DOI: 10.1158/2159-8290.CD-13-0044. View

20.

Nakayama K, Nakayama K . Ubiquitin ligases: cell-cycle control and cancer. Nat Rev Cancer. 2006; 6(5):369-81. DOI: 10.1038/nrc1881. View